Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Int J Med Sci ; 11(12): 1248-57, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25317071

RESUMEN

OBJECTIVE: Muscle loss and metabolic changes occur with disuse [i.e. bed rest (BR)]. We hypothesized that BR would lead to a metabolically unhealthy profile defined by: increased circulating tumor necrosis factor (TNF)-α, decreased circulating insulin-like-growth-factor (IGF)-1, decreased HDL-cholesterol, and decreased muscle density (MD; measured by mid-thigh computerized tomography). METHODS: We investigated the metabolic profile after 28 days of BR with 8 ± 6% energy deficit in male individuals (30-55 years) randomized to resistance exercise with amino acid supplementation (RT, n=24) or amino acid supplementation alone (EAA, n=7). Upper and lower body exercises were performed in the horizontal position. Blood samples were taken at baseline, after 28 days of BR and 14 days of recovery. RESULTS: We found a shift toward a metabolically unfavourable profile after BR [compared to baseline (BLN)] in both groups as shown by decreased HDL-cholesterol levels (EAA: BLN: 39 ± 4 vs. BR: 32 ± 2 mg/dL, RT: BLN: 39 ± 1 vs. BR: 32 ± 1 mg/dL; p<0.001) and Low MD (EAA: BLN: 27 ± 4 vs. BR: 22 ± 3 cm(2), RT: BLN: 28 ± 2 vs. BR: 23 ± 2 cm(2); p<0.001). A healthier metabolic profile was maintained with exercise, including NormalMD (EAA: BLN: 124 ± 6 vs. BR: 110 ± 5 cm(2), RT: BLN: 132 ± 3 vs. BR: 131 ± 4 cm(2); p<0.001, time-by-group); although, exercise did not completely alleviate the unfavourable metabolic changes seen with BR. Interestingly, both groups had increased plasma IGF-1 levels (EAA: BLN:168 ± 22 vs. BR 213 ± 20 ng/mL, RT: BLN:180 ± 10 vs. BR: 219 ± 13 ng/mL; p<0.001) and neither group showed TNFα changes (p>0.05). CONCLUSIONS: We conclude that RT can be incorporated to potentially offset the metabolic complications of BR.


Asunto(s)
Aminoácidos Esenciales/administración & dosificación , Reposo en Cama/efectos adversos , Metaboloma , Entrenamiento de Fuerza/métodos , Adulto , HDL-Colesterol/sangre , Suplementos Dietéticos , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Masculino , Persona de Mediana Edad , Músculo Esquelético/patología , Factor de Necrosis Tumoral alfa/sangre
2.
J Gerontol A Biol Sci Med Sci ; 76(7): 1206-1213, 2021 06 14.
Artículo en Inglés | MEDLINE | ID: mdl-33491048

RESUMEN

To understand the growing needs of an aging human population, there is demand for scalable and reproducible approaches to study animal models of aging and to test novel therapeutic interventions. We investigated the sensitivity and utility of a continuous monitoring platform and its digital biomarkers (motion, breathing rate, and wheel running) to evaluate behavioral and physiological differences between "young" (12 weeks) and "old" (23 months) male C57BL/6J mice with or without running wheels in the home cage. Compared to young mice, old mice showed marked reductions in motion and breathing rate, as well as altered circadian rhythms. Mice without running wheels possessed lower breathing rates compared to their counterparts with running wheels. Digital biomarkers showed age-dependent changes in response to routine procedures (cage changes and blood sampling) and alterations in subjects that unexpectedly reached endpoint. Continuous collection of digital biomarkers in the home cage can enhance current approaches by providing unbiased longitudinal monitoring for large-scale aging studies.


Asunto(s)
Envejecimiento/fisiología , Conducta Animal/fisiología , Biomarcadores/análisis , Monitoreo Fisiológico/instrumentación , Actividad Motora/fisiología , Animales , Automatización , Ritmo Circadiano/fisiología , Determinación de Punto Final , Masculino , Ratones , Ratones Endogámicos C57BL , Modelos Animales , Respiración
3.
Muscle Nerve ; 42(6): 927-35, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20928906

RESUMEN

Spaceflight and bed rest (BR) lead to muscle atrophy. This study assessed the effect of essential amino acid (EAA) supplementation and resistance training with decreased energy intake on molecular changes in skeletal muscle after 28-day BR and 14-day recovery. Thirty-one men (31-55 years) subjected to an 8 ± 6% energy deficit were randomized to receive EAA without resistance training (AA, n = 7), or EAA 3 h after (RT, n = 12) or 5 min before (AART, n = 12) resistance training. During BR, myostatin transcript levels increased twofold in the AA group. During recovery, insulin-like growth factor-1 (IGF-1) mRNA increased in all groups, whereas Pax7, MyoD, myogenin, and MRF4 transcripts increased in AA only (all P < 0.05). MAFbx transcripts decreased twofold with AA and RT. Satellite cells did not change during BR or recovery. This suggests that EAA alone is the least protective countermeasure to muscle loss, and several molecular mechanisms are proposed by which exercise attenuates muscle atrophy during BR with energy deficit.


Asunto(s)
Aminoácidos Esenciales/administración & dosificación , Reposo en Cama , Músculo Esquelético/metabolismo , Atrofia Muscular/metabolismo , Atrofia Muscular/terapia , Entrenamiento de Fuerza , Adulto , Aminoácidos Esenciales/metabolismo , Análisis de Varianza , Regulación hacia Abajo , Humanos , Inmunohistoquímica , Factor I del Crecimiento Similar a la Insulina/genética , Factor I del Crecimiento Similar a la Insulina/metabolismo , Masculino , Persona de Mediana Edad , Atrofia Muscular/genética , Proteína MioD/genética , Proteína MioD/metabolismo , Factores Reguladores Miogénicos/genética , Factores Reguladores Miogénicos/metabolismo , Miogenina/genética , Miogenina/metabolismo , Miostatina/genética , Miostatina/metabolismo , Factor de Transcripción PAX7/genética , Factor de Transcripción PAX7/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Regulación hacia Arriba
4.
Sci Rep ; 10(1): 2336, 2020 02 11.
Artículo en Inglés | MEDLINE | ID: mdl-32047211

RESUMEN

Animal models are useful for exploring the health consequences of prolonged spaceflight. Capabilities were developed to perform experiments in low earth orbit with on-board sample recovery, thereby avoiding complications caused by return to Earth. For NASA's Rodent Research-1 mission, female mice (ten 32 wk C57BL/6NTac; ten 16 wk C57BL/6J) were launched on an unmanned vehicle, then resided on the International Space Station for 21/22d or 37d in microgravity. Mice were euthanized on-orbit, livers and spleens dissected, and remaining tissues frozen in situ for later analyses. Mice appeared healthy by daily video health checks and body, adrenal, and spleen weights of 37d-flight (FLT) mice did not differ from ground controls housed in flight hardware (GC), while thymus weights were 35% greater in FLT than GC. Mice exposed to 37d of spaceflight displayed elevated liver mass (33%) and select enzyme activities compared to GC, whereas 21/22d-FLT mice did not. FLT mice appeared more physically active than respective GC while soleus muscle showed expected atrophy. RNA and enzyme activity levels in tissues recovered on-orbit were of acceptable quality. Thus, this system establishes a new capability for conducting long-duration experiments in space, enables sample recovery on-orbit, and avoids triggering standard indices of chronic stress.


Asunto(s)
Peso Corporal , Hígado/metabolismo , Vuelo Espacial , Ingravidez , Animales , Femenino , Perfilación de la Expresión Génica , Masculino , Ratones , Ratones Endogámicos C57BL , Tamaño de los Órganos , Factores de Tiempo
5.
Sci Rep ; 9(1): 10154, 2019 Jul 09.
Artículo en Inglés | MEDLINE | ID: mdl-31289284

RESUMEN

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

6.
Sci Rep ; 9(1): 4717, 2019 04 11.
Artículo en Inglés | MEDLINE | ID: mdl-30976012

RESUMEN

Interest in space habitation has grown dramatically with planning underway for the first human transit to Mars. Despite a robust history of domestic and international spaceflight research, understanding behavioral adaptation to the space environment for extended durations is scant. Here we report the first detailed behavioral analysis of mice flown in the NASA Rodent Habitat on the International Space Station (ISS). Following 4-day transit from Earth to ISS, video images were acquired on orbit from 16- and 32-week-old female mice. Spaceflown mice engaged in a full range of species-typical behaviors. Physical activity was greater in younger flight mice as compared to identically-housed ground controls, and followed the circadian cycle. Within 7-10 days after launch, younger (but not older), mice began to exhibit distinctive circling or 'race-tracking' behavior that evolved into coordinated group activity. Organized group circling behavior unique to spaceflight may represent stereotyped motor behavior, rewarding effects of physical exercise, or vestibular sensation produced via self-motion. Affording mice the opportunity to grab and run in the RH resembles physical activities that the crew participate in routinely. Our approach yields a useful analog for better understanding human responses to spaceflight, providing the opportunity to assess how physical movement influences responses to microgravity.


Asunto(s)
Adaptación Fisiológica/fisiología , Conducta Animal/fisiología , Animales , Femenino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Vuelo Espacial/métodos , Ingravidez
7.
Sci Rep ; 9(1): 9397, 2019 06 28.
Artículo en Inglés | MEDLINE | ID: mdl-31253821

RESUMEN

Microgravity exposure is associated with loss of muscle mass and strength. The E3 ubiquitin ligase MuRF1 plays an integral role in degrading the contractile apparatus of skeletal muscle; MuRF1 null (KO) mice have shown protection in ground-based models of muscle atrophy. In contrast, MuRF1 KO mice subjected to 21 days of microgravity on the International Space Station (ISS) were not protected from muscle atrophy. In a time course experiment microgravity-induced muscle loss on the ISS showed MuRF1 gene expression was not upregulated. A comparison of the soleus transcriptome profiles between spaceflight and a publicly available data set for hindlimb suspension, a claimed surrogate model of microgravity, showed only marginal commonalities between the models. These findings demonstrate spaceflight induced atrophy is unique, and that understanding of effects of space requires study situated beyond the Earth's mesosphere.


Asunto(s)
Hipogravedad , Proteínas Musculares/deficiencia , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Atrofia Muscular/etiología , Atrofia Muscular/metabolismo , Vuelo Espacial , Proteínas de Motivos Tripartitos/deficiencia , Ubiquitina-Proteína Ligasas/deficiencia , Animales , Susceptibilidad a Enfermedades , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Suspensión Trasera , Ratones , Ratones Noqueados , Atrofia Muscular/patología , Tamaño de los Órganos
8.
Cell Rep ; 29(3): 749-763.e12, 2019 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-31618641

RESUMEN

HDAC4, a class IIa histone deacetylase, is upregulated in skeletal muscle in response to denervation-induced atrophy. When HDAC4 is deleted postnatally, mice are partially protected from denervation. Despite the name "histone" deacetylase, HDAC4 demonstrably deacetylates cytosolic and non-histone nuclear proteins. We developed potent and selective class IIa HDAC inhibitors. Using these tools and genetic knockdown, we identified three previously unidentified substrates of HDAC4: myosin heavy chain, peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1α), and heat shock cognate 71 kDa protein (Hsc70). HDAC4 inhibition almost completely prevented denervation-induced loss of myosin heavy chain isoforms and blocked the action of their E3 ligase, MuRF1. PGC-1α directly interacts with class IIa HDACs; selective inhibitors increased PGC-1α protein in muscles. Hsc70 deacetylation by HDAC4 affects its chaperone activity. Through these endogenous HDAC4 substrates, we identified several muscle metabolic pathways that are regulated by class IIa HDACs, opening up new therapeutic options to treat skeletal muscle disorders and potentially other disease where these specific pathways are affected.


Asunto(s)
Proteínas del Choque Térmico HSC70/metabolismo , Histona Desacetilasas/metabolismo , Músculo Esquelético/metabolismo , Cadenas Pesadas de Miosina/metabolismo , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/metabolismo , Acetilación , Animales , Células Cultivadas , Femenino , Expresión Génica , Histona Desacetilasas/química , Histona Desacetilasas/genética , Masculino , Ratones , Ratones Noqueados , Proteínas Musculares/metabolismo , Mioblastos/citología , Mioblastos/metabolismo , Cadenas Pesadas de Miosina/genética , Unión Proteica , Isoformas de Proteínas/metabolismo , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Receptores de Glucocorticoides/metabolismo , Proteínas de Motivos Tripartitos/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo
9.
Cell Rep ; 28(11): 2767-2776.e5, 2019 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-31509740

RESUMEN

The hormone αKlotho regulates lifespan in mice, as knockouts die early of what appears to be accelerated aging due to hyperphosphatemia and soft tissue calcification. In contrast, the overexpression of αKlotho increases lifespan. Given the severe mouse phenotype, we generated zebrafish mutants for αklotho as well as its binding partner fibroblast growth factor-23 (fgf23). Both mutations cause shortened lifespan in zebrafish, with abrupt onset of behavioral and degenerative physical changes at around 5 months of age. There is a calcification of vessels throughout the body, most dramatically in the outflow tract of the heart, the bulbus arteriosus (BA). This calcification is associated with an ectopic activation of osteoclast differentiation pathways. These findings suggest that the gradual loss of αKlotho found in normal aging might give rise to ectopic calcification.


Asunto(s)
Glucuronidasa/metabolismo , Longevidad/genética , Osteogénesis/genética , Calcificación Vascular/metabolismo , Pez Cebra/metabolismo , Animales , Animales Modificados Genéticamente , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/genética , Factores de Crecimiento de Fibroblastos/metabolismo , Técnicas de Inactivación de Genes , Glucuronidasa/genética , Corazón , Inflamación/genética , Inflamación/metabolismo , Riñón/metabolismo , Proteínas Klotho , Masculino , Mutación , Miocardio/metabolismo , RNA-Seq , Transducción de Señal/genética , Calcificación Vascular/genética , Calcificación Vascular/mortalidad , Pez Cebra/genética
10.
J Appl Physiol (1985) ; 105(1): 241-8, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18483167

RESUMEN

Spaceflight and bed rest (BR) result in losses of muscle mass and strength. Resistance training (RT) and amino acid (AA) supplementation are potential countermeasures to minimize these losses. However, it is unknown if timing of supplementation with exercise can optimize benefits, particularly with energy deficit. We examined the effect of these countermeasures on body composition, strength, and insulin levels in 31 men (ages 31-55 yr) during BR (28 days) followed by active recovery (14 days). Subjects were randomly assigned to essential AA supplementation (AA group, n = 7); RT with AA given 3 h after training (RT group, n = 12); or RT with AA given 5 min before training (AART group, n = 12). Energy intake was reduced by 8 +/- 6%. Midthigh muscle area declined with BR for the AA > RT > AART groups: -11%, -3%, -4% (P = 0.05). Similarly, greatest losses in lower body muscle strength were seen in the AA group (-22%). These were attenuated in the exercising groups [RT (-8%) and AART (-6%; P < 0.05)]. Fat mass and midthigh intramuscular fat increased after BR in the AA group (+3% and +14%, respectively), and decreased in the RT (-5% and -4%) and AART groups (-1 and -5%; P = 0.05). Muscle mass and strength returned toward baseline after recovery, but the AA group showed the lowest regains. Combined resistance training with AA supplementation pre- or postexercise attenuated the losses in muscle mass and strength by approximately two-thirds compared with AA supplement alone during BR and energy deficit. These data support the efficacy of combined AA and RT as a countermeasure against muscle wasting due to low gravity.


Asunto(s)
Aminoácidos Esenciales/farmacología , Metabolismo Energético/fisiología , Músculo Esquelético/fisiología , Aptitud Física/fisiología , Descanso/fisiología , Levantamiento de Peso/fisiología , Absorciometría de Fotón , Adulto , Composición Corporal/efectos de los fármacos , Composición Corporal/fisiología , Ingestión de Energía/fisiología , Metabolismo Energético/efectos de los fármacos , Humanos , Insulina/sangre , Masculino , Persona de Mediana Edad , Fuerza Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Tamaño de los Órganos/efectos de los fármacos , Tomografía Computarizada por Rayos X
11.
Cell Rep ; 22(6): 1522-1530, 2018 02 06.
Artículo en Inglés | MEDLINE | ID: mdl-29425507

RESUMEN

The age-related effects of GDF11 have been a subject of controversy. Here, we find that elevated GDF11 causes signs of cachexia in mice: reduced food intake, body weight, and muscle mass. GDF11 also elicited a significant elevation in plasma Activin A, previously shown to contribute to the loss of skeletal muscle. The effects of GDF11 on skeletal muscle could be reversed by administration of antibodies to the Activin type II receptors. In addition to the effects on muscle, GDF11 increased plasma GDF15, an anorectic agent. The anorexia, but not the muscle loss, could be reversed with a GDF15-neutralizing antibody. GDF15 upregulation is due to GDF11-induced recruitment of SMAD2/3 to the GDF15 promoter. Inhibition of GDF15 can restore appetite but cannot restore the GDF11-induced loss of muscle mass, which requires blockade of ActRII signaling. These findings are relevant for treatment of cachexia.


Asunto(s)
Proteínas Morfogenéticas Óseas/metabolismo , Caquexia , Factor 15 de Diferenciación de Crecimiento/biosíntesis , Factores de Diferenciación de Crecimiento/metabolismo , Activinas/metabolismo , Animales , Proteínas Morfogenéticas Óseas/farmacología , Factores de Diferenciación de Crecimiento/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Regulación hacia Arriba
12.
Cell Metab ; 22(1): 164-74, 2015 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-26001423

RESUMEN

Age-related frailty may be due to decreased skeletal muscle regeneration. The role of TGF-ß molecules myostatin and GDF11 in regeneration is unclear. Recent studies showed an age-related decrease in GDF11 and that GDF11 treatment improves muscle regeneration, which were contrary to prior studies. We now show that these recent claims are not reproducible and the reagents previously used to detect GDF11 are not GDF11 specific. We develop a GDF11-specific immunoassay and show a trend toward increased GDF11 levels in sera of aged rats and humans. GDF11 mRNA increases in rat muscle with age. Mechanistically, GDF11 and myostatin both induce SMAD2/3 phosphorylation, inhibit myoblast differentiation, and regulate identical downstream signaling. GDF11 significantly inhibited muscle regeneration and decreased satellite cell expansion in mice. Given early data in humans showing a trend for an age-related increase, GDF11 could be a target for pharmacologic blockade to treat age-related sarcopenia.


Asunto(s)
Proteínas Morfogenéticas Óseas/metabolismo , Factores de Diferenciación de Crecimiento/metabolismo , Músculo Esquelético/fisiología , Regeneración , Envejecimiento , Animales , Proteínas Morfogenéticas Óseas/sangre , Proteínas Morfogenéticas Óseas/genética , Diferenciación Celular , Línea Celular , Factores de Diferenciación de Crecimiento/sangre , Factores de Diferenciación de Crecimiento/genética , Humanos , Ratones , Mioblastos/citología , Mioblastos/metabolismo , Miostatina/metabolismo , Ratas , Transducción de Señal , Regulación hacia Arriba
13.
Nat Med ; 20(4): 408-14, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24658078

RESUMEN

Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, which is EPO independent. Here we investigated regulation of erythropoiesis using a ligand-trapping fusion protein (ACE-536) containing the extracellular domain of human activin receptor type IIB (ActRIIB) modified to reduce activin binding. ACE-536, or its mouse version RAP-536, produced rapid and robust increases in erythrocyte numbers in multiple species under basal conditions and reduced or prevented anemia in murine models. Unlike EPO, RAP-536 promoted maturation of late-stage erythroid precursors in vivo. Cotreatment with ACE-536 and EPO produced a synergistic erythropoietic response. ACE-536 bound growth differentiation factor-11 (GDF11) and potently inhibited GDF11-mediated Smad2/3 signaling. GDF11 inhibited erythroid maturation in mice in vivo and ex vivo. Expression of GDF11 and ActRIIB in erythroid precursors decreased progressively with maturation, suggesting an inhibitory role for GDF11 in late-stage erythroid differentiation. RAP-536 treatment also reduced Smad2/3 activation, anemia, erythroid hyperplasia and ineffective erythropoiesis in a mouse model of myelodysplastic syndromes (MDS). These findings implicate transforming growth factor-ß (TGF-ß) superfamily signaling in erythroid maturation and identify ACE-536 as a new potential treatment for anemia, including that caused by ineffective erythropoiesis.


Asunto(s)
Receptores de Activinas Tipo II , Anemia/sangre , Proteínas Morfogenéticas Óseas/efectos de los fármacos , Células Precursoras Eritroides/efectos de los fármacos , Eritropoyesis/efectos de los fármacos , Factores de Diferenciación de Crecimiento/efectos de los fármacos , Hematínicos/farmacología , Síndromes Mielodisplásicos/sangre , Proteínas Recombinantes de Fusión/farmacología , Animales , Proteínas Morfogenéticas Óseas/antagonistas & inhibidores , Modelos Animales de Enfermedad , Quimioterapia Combinada , Recuento de Eritrocitos , Eritropoyetina/farmacología , Factores de Diferenciación de Crecimiento/antagonistas & inhibidores , Haplorrinos , Humanos , Ligandos , Ratones , Ratas , Recuento de Reticulocitos , Transducción de Señal/efectos de los fármacos , Proteína Smad2/efectos de los fármacos , Proteína smad3/efectos de los fármacos
15.
J Appl Physiol (1985) ; 109(3): 635-42, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20466801

RESUMEN

This is the first report that inhibition of negative regulators of skeletal muscle by a soluble form of activin type IIB receptor (ACE-031) increases muscle mass independent of fiber-type expression. This finding is distinct from the effects of selective pharmacological inhibition of myostatin (GDF-8), which predominantly targets type II fibers. In our study 8-wk-old C57BL/6 mice were treated with ACE-031 or vehicle control for 28 days. By the end of treatment, mean body weight of the ACE-031 group was 16% greater than that of the control group, and wet weights of soleus, plantaris, gastrocnemius, and extensor digitorum longus muscles increased by 33, 44, 46 and 26%, respectively (P<0.05). Soleus fiber-type distribution was unchanged with ACE-031 administration, and mean fiber cross-sectional area increased by 22 and 28% (P<0.05) in type I and II fibers, respectively. In the plantaris, a predominantly type II fiber muscle, mean fiber cross-sectional area increased by 57% with ACE-031 treatment. Analysis of myosin heavy chain (MHC) isoform transcripts by real-time PCR indicated no change in transcript levels in the soleus, but a decline in MHC I and IIa in the plantaris. In contrast, electrophoretic separation of total soleus and plantaris protein indicated that there was no change in the proportion of MHC isoforms in either muscle. Thus these data provide optimism that ACE-031 may be a viable therapeutic in the treatment of musculoskeletal diseases. Future studies should be undertaken to confirm that the observed effects are not age dependent or due to the relatively short study duration.


Asunto(s)
Receptores de Activinas Tipo II/administración & dosificación , Desarrollo de Músculos/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Receptores de Activinas Tipo II/genética , Animales , Regulación de la Expresión Génica , Humanos , Hipertrofia , Fragmentos Fc de Inmunoglobulinas/genética , Inmunoglobulina G/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Fibras Musculares de Contracción Rápida/efectos de los fármacos , Fibras Musculares de Contracción Rápida/metabolismo , Fibras Musculares de Contracción Lenta/efectos de los fármacos , Fibras Musculares de Contracción Lenta/metabolismo , Músculo Esquelético/crecimiento & desarrollo , Músculo Esquelético/metabolismo , Cadenas Pesadas de Miosina/genética , Cadenas Pesadas de Miosina/metabolismo , Miostatina/antagonistas & inhibidores , Tamaño de los Órganos , Isoformas de Proteínas , ARN Mensajero/metabolismo , Proteínas Recombinantes de Fusión/administración & dosificación , Factores de Tiempo , Aumento de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA